National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
Clinical Trials at NIH Home

Clinical Trials by Cancer Site

Lymphoma

Lymphoma is a disease that affects both children and adults, and a disease that is more prevalent in adult Caucasian males. The cause for most of the lymphoma cases is unknown, but some risk factors involve family history, severely reduced immune function due to organ transplants, autoimmune disease, HIV/AIDS, Human T-cell leukemia/lymphoma virus-I (HTLV-I), Epstein-Barr virus (EBV), history of helicobacter pylori infection, hepatitis C virus, occupational exposure to herbicides and pesticides, and a diet high in meats and fat.

Treatment options may vary depending on the type of lymphoma, stage of the disease, patient's age, and other medical conditions, and should be discussed with the patient's physician.

Lymphoma Clinical Trials

The Center for Cancer Research (CCR), NCI's largest division doing research on campus, conducts lymphoma clinical trials at the NIH Clinical Center in Bethesda, Md. NCI accepts referrals to lymphoma clinical trials conducted in Bethesda, Md., through its Clinical Trials Referral Office (formerly called the Clinical Studies Support Center) at 1-888-NCI-1937 (1-888-624-1937).

NCI is currently conducting the following trials for patients with lymphoma. Click on the trials below for additional details, including a summary of eligibility criteria, treatment plan, and information on how to contact the principal investigators and their staff directly.


  
Trial and Protocol Number
Lymphoma
Phase III
Phase III Randomized Study of R-CHOP Versus Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
NCI-05-C-0252

Principal Investigator:Referral Contact:
Wyndham H. WilsonPeggy Shovlin
301-435-2415301-594-6597
mshovlin@mail.nih.gov
Phase II
A Phase II, Multicenter, Open-Label Trial Evaluating the Activity and Tolerability of Romidepsin (Depsipeptide, FK228) in Progressive or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy
NCI-08-C-0164

Principal Investigator:Referral Contact:
Richard PiekarzRobin Frye
301-496-1196301-402-5958
fryer@mail.nih.gov
Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics
NCI-05-C-0170

Principal Investigator:Referral Contact:
Wyndham H. WilsonTherese White
301-435-2415301-402-5886
whiteth@mail.nih.gov
Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas
NCI-04-C-0173

Principal Investigator:Referral Contact:
Wyndham H. WilsonPeggy Shovlin
301-435-2415301-594-6597
mshovlin@mail.nih.gov
A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Cutaneous T-Cell Lymphomas
NCI-04-C-0142

Principal Investigator:Referral Contact:
Robert J. KreitmanLinda Ellison
301-496-6947301-496-9458
ellisonl@mail.nih.gov
A Pilot Study of MDX-CTLA-4 in Lymphoma
NCI-02-C-0284

Principal Investigator:Referral Contact:
John E. JanikDebbie Draper
301-402-2913301-435-8525
draperde@mail.nih.gov
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Patients With Aggressive Non-Hodgkin’s Lymphoma
NCI-93-C-0133 (Multi-center study)

Principal Investigator:Referral Contact:
Wyndham H. WilsonTherese White
301-435-2415301-402-5886
whiteth@mail.nih.gov
Phase I/II
A Phase I/II Study of Flavopiridol in Relapsed or Refractory Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
NCI-07-C-0081

Principal Investigator:Referral Contact:
Kieron DunleavyTherese White
301-435-1007301-402-5886
whiteth@mail.nih.gov
A Phase I/IIa Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
NCI-07-C-0006

Principal Investigator:Referral Contact:
Wyndham H. WilsonPeggy Shovlin
301-435-2415301-594-6597
mshovlin@mail.nih.gov
A Phase I/II Study of Tac-Expressing Malignancies (Other than ATL) with Yttrium-90 (90Y)-Radiolabeled Humanized Anti-Tac and Calcium-DTPA
NCI-97-C-0110F

Principal Investigator:Referral Contact:
Thomas WaldmannSuzanne Fioravanti
301-496-6656301-594-6544
fioravas@mail.nih.gov
Phase I
Phase I Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in T- and NK-Cell Lymphomas
NCI-09-C-0065

Principal Investigator:Referral Contact:
John E. JanikTherese White
301-402-2913301-402-5886
whiteth@mail.nih.gov
Phase I Pilot Study of Topical Romidepsin in Patients With Stage IA, IB, or IIA Cutaneous T-Cell Non-Hodgkin’s Lymphoma
NCI-07-C-0133

Principal Investigator:Referral Contact:
Maria L. TurnerEffie Nomicos
301-496-7737301-402-6225
Phone: 866-510-9104 (Toll Free)
enomicos@mail.nih.gov
No Phase
Pathogenesis and Course of Cutaneous T-Cell Lymphoma
NCI-04-C-0081

Principal Investigator:Referral Contact:
Maria L. TurnerSusan Booher
301-496-7737301-402-1474
boohers@mail.nih.gov


  
Trial and Protocol Number
Lymphomatoid Granulomatosis
Phase II
Treatment and Natural History Study of Lymphomatoid Granulomatosis
NCI-94-C-0074

Principal Investigator:Referral Contact:
Wyndham H. WilsonNicole Grant
301-435-2415301-594-2947
grantn@mail.nih.gov


  
Trial and Protocol Number
AIDS Related Cancers
Phase II
AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy
NCI-06-C-0051

Principal Investigator:Referral Contact:
Robert YarchoanKaren Aleman
301-496-8959301-496-8959
1-800-243-2732 ext. 4 (Toll Free)
alemank@mail.nih.gov
Short-Course EPOCH-Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
NCI-01-C-0030

Principal Investigator:Referral Contact:
Wyndham H. WilsonNicole Grant
301-435-2415301-594-2947
grantn@mail.nih.gov


  
Trial and Protocol Number
Graft-Versus-Host Disease
No Phase
Prospective Assessment of Clinical and Biological Factors Determining Outcomes in Patients With Chronic Graft-Versus-Host Disease (GVHD)
NCI-04-C-0281

Principal Investigator:Referral Contact:
Steven Z. PavleticCaroline Stewart
301-402-4899301-451-6569
cstewartv@mail.nih.gov


  
Trial and Protocol Number
Hematologic/Blood Cancers
Pilot
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders
NCI-09-C-0210

Principal Investigator:Referral Contact:
Michael R. BishopZetta Blacklock
301-435-2764301-594-2056
bblacklock@mail.nih.gov
Phase II
Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome
NCI-04-C-0055

Principal Investigator:Referral Contact:
Daniel FowlerZetta Blacklock
301-435-8641301-594-2056
bblacklock@mail.nih.gov
Phase I/II
Phase I/II Study of B-Cell Malignancies Using T Cells Expressing an Anti-DC19 Chimeric Receptor: Assessment of the Impact of Lymphocyte Depletion Prior to T-Cell Transfer
NCI-09-C-0082

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505
(Toll Free)		1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies
NCI-08-C-0051

Principal Investigator:Referral Contact:
Alan WaynePediatric Oncology
301-496-42561-877-624-4878
(Toll free)

Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-Matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders
NCI-07-C-0195

Principal Investigator:Referral Contact:
Michael R. BishopZetta Blacklock
301-435-2764301-594-2056
bblacklock@mail.nih.gov
Pilot Study of Non-Myeloablative, HLA-matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
NCI-01-C-0125

Principal Investigator:Referral Contact:
Alan WaynePediatric Oncology
301-496-42561-877-624-4878
(Toll free)

Phase I
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents, and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin’s Lymphoma (NHL)
NCI-08-C-0123

Principal Investigator:Referral Contact:
Alan WaynePediatric Oncology
301-496-42561-877-624-4878
(Toll free)

Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated, Tumor-Derived Lymphocytes
NCI-07-C-0064

Principal Investigator:Referral Contact:
Michael R. BishopZetta Blacklock
301-435-2764301-594-2056
bblacklock@mail.nih.gov
Multi-Institutional Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
NCI-06-C-0227

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-5402301-435-2715
jbingham@mail.nih.gov
T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors for Hematologic Malignancies
NCI-04-C-0116

Principal Investigator:Referral Contact:
Michael R. BishopZetta Blacklock
301-435-2764301-594-2056
bblacklock@mail.nih.gov


  
Trial and Protocol Number
Leukemia
Phase II
Phase II Study of the Efficacy and Toxicity of Ontak® (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
NCI-05-C-0185

Principal Investigator:Referral Contact:
John E. JanikSuzanne Fioravanti
301-402-2913301-594-6544
fioravas@mail.nih.gov
Phase I/II
Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax®) in the Therapy of Tac-Expressing Adult T-Cell Leukemia
NCI-00-C-0030

Principal Investigator:Referral Contact:
John C. MorrisSuzanne Fioravanti
301-402-2912301-594-6544
fioravas@mail.nih.gov


  
Trial and Protocol Number
Solid Tumor
Phase I
A Phase I, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies
NCI-09-C-0111

Principal Investigator:Referral Contact:
Susan BatesDebbie Draper
301-402-1357301-435-8525
draperde@mail.nih.gov
A Phase I Study of ABT-888 in Combination With Metronomic Cyclophosphamide in Adults With Refractory Solid Tumors and Lymphomas
NCI-09-C-0048

Principal Investigator:Referral Contact:
Shivaani KummarDeborah Allen
301-435-5402301-402-5640
allendeb@mail.nih.gov
A Phase I and Pharmacokinetic Single-Agent Study of Pazopanib in Adults With Advanced Malignancies and Varying Degrees of Liver Dysfunction
NCI-09-C-0003

Principal Investigator:Referral Contact:
Shivaani KummarLaura D. Otten
301-435-5402301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
Phase I Study of SNX-5422 Mesylate in Adults With Refractory Solid Tumor Malignancies and Lymphomas
NCI-08-C-0091

Principal Investigator:Referral Contact:
Giuseppe GiacconeJanelle Bingham
301-496-4916301-435-2715
jbingham@mail.nih.gov
Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-SorbTM (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas
NCI-08-C-0030

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-5402301-435-2715
jbingham@mail.nih.gov
A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer
NCI-08-C-0007

Principal Investigator:Referral Contact:
Crystal MackallPediatric Oncology
301-402-59401-877-624-4878
(Toll free)

A Phase I Study of Batracylin (NSC320846) in Subjects With Solid Tumors and Lymphomas
NCI-07-C-0097

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-5402301-435-2715
jbingham@mail.nih.gov
Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients With Refractory Pediatric Solid Tumors
NCI-07-C-0040

Principal Investigator:Referral Contact:
Crystal MackallPediatric Oncology
301-402-59401-877-624-4878
(Toll free)



Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov National Cancer Institute Clinical Trials at NIH - Be part of the cure